Pasithea Therapeutics Corp.
KTTA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | -14.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -29,916.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -14,430.5% |
| EPS Diluted | -12.69 | -13.01 | -10.34 | -1.89 |
| % Growth | 2.5% | -25.8% | -447.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |